Zerbaxa (Ceftolozane/Tazobactam) Patent Expiration, LOE Window & CMS Spending

Zerbaxa (Ceftolozane/Tazobactam) by Merck & Co.: FDA Orange Book core substance LOE 2034-11-28 (last listed 2036-02-14), 0 AB generics, $24.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN206829 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-11-28
Last Listed Patent or Exclusivity Date2036-02-14
Orange Book Patents (*PED Extensions)24 patents (12 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$24.1M
2024 Medicare Part D Spend$18.0M
2024 Medicaid Spend$6.1M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 32.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.